公共卫生导向的毒品法律改革对墨西哥蒂华纳注射吸毒者HIV发病率的影响:一项流行病学模型研究
该流行病学建模研究利用El Cuete IV队列数据构建2012至2030年蒂华纳注射吸毒者HIV传播的确定性模型,评估墨西哥narcomenudeo改革的效果。模型估计2012至2017年有限实施避免了2%(95%CI 0.2-3.0)的新发HIV感染;若2018年起监禁减少80%,2018至2030年可避免9%(95%CI 4-16)的新发感染,若转介至阿片类激动剂治疗则可避免21%(10-33),而转介至强制戒毒方案则为-2%(95%CI -23至9)。作者认为改革对HIV流行影响甚微,但若与阿片类激动剂治疗联动则可能显著降低HIV发病率。
要点
- 2011年改革前,El Cuete队列733名注射吸毒者中547人(75%)报告曾入狱,开始注射以来平均5次。
- 模型估计2012-2017年有限改革实施避免了2%(95%CI 0.2-3.0)的新发HIV感染。
- 若2018年起监禁减少80%,可避免9%(95%CI 4-16)新发感染;转介至阿片类激动剂治疗可避免21%(10-33);转介至强制戒毒方案为-2%(95%CI -23至9)。
核心结论
- 墨西哥毒品法律改革对蒂华纳注射吸毒者中的HIV流行影响甚微,但若与阿片类激动剂治疗联动且适当实施,可显著降低HIV发病率。
- 强制戒毒方案是主要可用的康复类型,其扩大可能潜在地增加HIV传播。
研究设计与样本
- 流行病学建模研究,使用El Cuete IV队列研究数据构建2012至2030年蒂华纳注射吸毒者注射与性传播HIV的确定性模型。
- 人群按性别、监禁状态、警方没收注射器、HIV分期及暴露于药物治疗或康复(阿片类激动剂治疗或强制戒毒方案)分层。
- 建模估计观察到的和潜在未来改革实施水平对注射吸毒者HIV风险的影响。
主要发现
- 2011年改革前,El Cuete队列733名注射吸毒者中547人(75%)报告曾入狱,开始注射以来平均5次。
- 模型估计2012至2017年有限改革实施避免了2%(95%CI 0.2-3.0)的新发HIV感染。
- 若2018年起监禁减少80%,2018至2030年可避免9%(95%CI 4-16)的新发HIV感染。
- 若转介至阿片类激动剂治疗而非监禁,可避免21%(95%CI 10-33)的新发感染。
- 若转介至强制戒毒方案而非监狱,避免感染为-2%(95%CI -23至9),影响较低或可能为负。
关键数值与推荐
- 2011年改革前,El Cuete队列733名注射吸毒者中547人(75%)报告曾入狱,开始注射以来平均5次。
- 2012至2017年有限改革实施避免了2%(95%CI 0.2-3.0)的新发HIV感染。
- 若2018年起监禁减少80%,2018至2030年可避免9%(95%CI 4-16)的新发HIV感染。
- 若转介至阿片类激动剂治疗而非监禁,可避免21%(95%CI 10-33)的新发感染。
- 若转介至强制戒毒方案而非监狱,避免感染为-2%(95%CI -23至9)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: As countries embark on public health-oriented drug law reform, health impact evaluations are needed. In 2012, Mexico mandated the narcomenudeo reform, which depenalised the possession of small amounts of drugs and instituted drug treatment instead of incarceration. We investigated the past and future effect of this drug law reform on HIV incidence in people who inject drugs in Tijuana, Mexico. METHODS: In this epidemic modelling study, we used data from the El Cuete IV cohort study to develop a deterministic model of injecting and sexual HIV transmission in people who inject drugs in Tijuana between 2012 and 2030. The population was stratified by sex, incarceration status, syringe confiscation by the police, HIV stage, and exposure to drug treatment or rehabilitation (either opioid agonist treatment or compulsory drug abstinence programmes). We modelled the effect of these exposures on HIV risk in people who inject drugs, estimating the effect of observed and potential future reform enforcement levels. FINDINGS: In 2011, prior to the narcomenudeo reform, 547 (75%) of 733 people who inject drugs in the El Cuete cohort reported having ever been incarcerated, on average five times since starting injecting. Modelling estimated the limited reform implementation averted 2% (95% CI 0·2-3·0) of new HIV infections in people who inject drugs between 2012 and 2017. If implementation reduced incarceration in people who inject drugs by 80% from 2018 onward, 9% (95% CI 4-16) of new HIV infections between 2018 and 2030 could be averted, with 21% (10-33) averted if people who inject drugs were referred to opioid agonist treatment instead of being incarcerated. Referral to compulsory drug abstinence programmes instead of prison could have a lower or potentially negative impact with -2% (95% CI -23 to 9) infections averted. INTERPRETATION: Mexican drug law reform has had a negligible effect on the HIV epidemic among people who inject drugs in Tijuana. However, appropriate implementation could markedly reduce HIV incidence if linked to opioid agonist treatment. Unfortunately, compulsory drug abstinence programmes are the main type of drug rehabilitation available and their expansion could potentially increase HIV transmission. FUNDING: National Institute on Drug Abuse, UC San Diego Center for AIDS Research.
引用
- Borquez A, Beletsky L, Nosyk B, et al. The effect of public health-oriented drug law reform on HIV incidence in people who inject drugs in Tijuana, Mexico: an epidemic modelling study. Lancet Public Health. 2018. PMID: 30122559. doi:10.1016/S2468-2667(18)30097-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。